Prialt

RSS

ziconotide

Authorised
This medicine is authorised for use in the European Union.

Overview

This is a summary of the European public assessment report (EPAR) for Prialt. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Prialt.

This EPAR was last updated on 25/10/2022

Authorisation details

Product details
Name
Prialt
Agency product number
EMEA/H/C/000551
Active substance
ziconotide
International non-proprietary name (INN) or common name
ziconotide
Therapeutic area (MeSH)
  • Injections, Spinal
  • Pain
Anatomical therapeutic chemical (ATC) code
N02BG08
Publication details
Marketing-authorisation holder
Esteve Pharmaceuticals GmbH
Revision
29
Date of issue of marketing authorisation valid throughout the European Union
21/02/2005
Contact address

Hohenzollerndamm 150-151
14199 Berlin
Germany

Product information

25/10/2022 Prialt - EMEA/H/C/000551 - II/0074

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.

 

Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Analgesics

Therapeutic indication

Ziconotide is indicated for the treatment of severe, chronic pain in patients who require intrathecal (IT) analgesia.

Assessment history

How useful was this page?

Add your rating
Average
2 ratings
3 ratings